老虎证券

BUZZ-Inozyme Pharma rises over 175% on $270 million buyout deal with BioMarin

Reuters
05/16
BUZZ-<a href="https://laohu8.com/S/INZY">Inozyme Pharma</a> rises over 175% on $270 million buyout deal with BioMarin

** Shares of rare disease therapy developer Inozyme Pharma INZY.O rise 179% to $3.96 premarket

** BioMarin Pharma BMRN.O says that it has entered into an agreement to buy Inozyme Pharma for $4 per share in an all-cash transaction for a total consideration of around $270 million

** The deal is expected to close in Q3 2025

** The deal will strengthen BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701, which is currently being assessed to treat a rare genetic disorder affecting blood vessels, soft tissues and bones, BMRN says

** As of last close, INZY down 48.7% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10